Use of a Label-Free Platform in a preclinical Contract Research Organization Environment
Caliper Discovery Alliances & Services (CDAS) is a Contract Research Organization offering comprehensive in vitro and in vivo preclinical contract research services. Their offering is articulated around different platforms including Target Validation with the creation of transgenic animals, Assay Development, Screening, Safety Pharmacology, Biochemical and Functional cell based profiling, Drug Efficacy in disease models and non-invasive small animal Optical Imaging.
NovaScreen Biosciences, now part of CDAS, pioneered receptor profiling studies in the early 1990’s and has established a best in class safety pharmacology platform with a large number of GPCR binding assays. Functional studies are very complementary to affinity-based radioligand assays as they provide very valuable information on the way a drug interacts with a GPCR target.
Using CDAS GPCRFunctional™ programs, you can determine if a drug is an activator or an inhibitor or what its potency and efficacy are for a given GPCR target. Understanding drug functionality is also an important benefit of functional studies and you can for example identify allosteric modulators that are generally difficult to identify using orthosteric ligand-based radioligand binding assays.